Merck & Co., Inc. MRK
NYSE · Healthcare · Drug Manufacturers - General
$133.72
Close on Fri, 20 Nov 2026 · market value $330B
What the price is betting on
Below its recordAt $134, the price assumes revenue shrinks about 0.7% a year for five years, from $67.3B to about $65.2B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 6.4% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than MRK? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$151
Base
$170
Bull
$191
Today $134
- Bear $151. Cash flow grows 1% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $170. Cash flow grows 3% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $191. Cash flow grows 5% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$67.2B$67.2B, on the path
- FY2027$66.7B$69.4B, on the path
- FY2028$66.2B$73.6B, on the path
- FY2029$65.7B$74.2B, on the path
- FY2030$65.2B$74.9B, on the path
Each year's revenue at −0.7% growth from $67.3B in the 12 months to September 2026.
At a glance
Healthcare · Drug Manufacturers - General · listed on NYSE
- Revenue, FY2025
- $64.9B
- Growth, 3 years a year
- 4.2%
- Cash margin
- 19%
- Net debt
- $36B
- Shares, 3-year change
- −1.4%
- Dividend yield
- 2.5%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.